Key Areas of Research for 2016-2017
BCRF funds a diverse array of research topics and areas of focus, including the following major impact areas.
Metastatic Breast Cancer Research
- This year, nearly one-third of BCRF 's grants (more than $16 million) are focused on metastatic breast cancer. Studies include understanding the biology of why and how cancer cells spread, the development of new treatments for advanced disease, and correlative studies to discover biomarkers that can predict which breast cancers are more likely to spread.
- In 2014, BCRF established the Evelyn H. Lauder Founder's Fund, a multi-year international program dedicated to metastasis that is the first large-scale global effort to unravel the biology of metastasis. BCRF has committed $31 million to date for the Founder's Fund Initiative in the US and Europe.
- BCRF is committing more than $23 million to research on improving treatments for breast cancer patients. Studies include understanding why a treatment fails some patients and not others, why tumors become resistant to drugs, and discovering biomarkers that can match patients to the right therapy.
- BCRF launched the Drug Research Collaborative, an unprecedented new funding model aimed at bridging the gap between academic researchers and access to new therapies, increasing patient access to clinical trials for a new drug or drug combinations.
- BCRF is investing over $10 million in research focused on immunotherapies, from novel combinations and clinical trials to vaccine development.
Inherited Susceptibility and Tumor Genomics
- Family history, genetics and race/ ethnicity all contribute to an individual's risk of breast cancer. Tumor genetic factors that are not inherited also influence the outcomes in breast cancer. In 2016-17, BCRF is investing over $15 million in research in inherited susceptibility and tumor genomics. Studies include understanding how mutations in the breast cancer genes BRCA1 and BRCA2 modify risk, identifying new breast cancer susceptibility genes and predicting the risk they have on developing breast cancer, and understanding how factors within the tumor influences tumor behavior.
Early Diagnosis and Prevention
- BCRF is committing $8 million to preventative research, including studies to understand the biology underlying the relationship between obesity and breast cancer risk, discover biomarkers in blood and tissue that can identify persons at risk, understand the early influence of diet and weight on future breast cancer risk, and decipher the long-term benefit of chemopreventives such as tamoxifen and aromatase inhibitors in high-risk women.
- BCRF is committed to addressing the diverse factors affecting disparities in breast cancer outcomes. In 2016-2017 BCRF has committed nearly $2 million in studies to understand the differences in genetic and biological risk factors across populations, improve access to genetic testing in high-risk minority groups, as well as access to quality care and affordable medications to underserved populations, and increase minority participation in clinical trials.
- This year, BCRF will be funding a research study through the Metastatic Breast Cancer Project (MBC Project) aimed specifically at examining the genomics of African-American women with metastatic breast cancer in hopes of understanding new approaches to preventing or treating metastases—a problem that is especially prevalent for black women.
Breast Cancer as a Growing Global Threat
- As cancer's toll grows around the world, it is becoming just as much a threat to global health and development as infectious diseases. In fact, the World Health Organization predicts that more people will die from cancer by 2030 than from AIDS, malaria and tuberculosis combined. For 2016-2017, BCRF's global presence is reflected in its support of 27 international researchers in 14 countries totaling more than $4.5 million in grants outside the US.
Learn more about these projects by tuning in to BCRF Conversations, the official podcast of BCRF. Available on iTunes and bcrfcure.org/podcasts.
Meghan Finn, Chief Communications & Engagement Officer | O: 646.497.2609 | C: 914.275.1981 | firstname.lastname@example.org
Sadia Zapp, Director of Communications | O: 646.497.2639 | C: 347.624.7926 | email@example.com
Deanna Clevesy, Manager, Communications | O: 646.497.2696 | firstname.lastname@example.org
Logo - http://photos.prnewswire.com/prnh/20160414/355612LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-breast-cancer-research-foundation-commits-57-million-to-fund-cancer-research-worldwide-300337784.html
SOURCE Breast Cancer Research Foundation